Apotex Loses Moot Appeal On Canadian Zytiga Bar
Second Action Favored Apotex In January 2021
Apotex fell again in its bid to prove that a key patent in Canada shielding Janssen’s Zytiga (abiraterone acetate) treatment for prostate cancer was obvious. However, the company had already succeeded in obtaining a marketing authorization in a separate action.
You may also be interested in...
The sole US patent listed against Janssen’s Zytiga abiraterone prostate-cancer treatment is invalid, the US Court of Appeals has confirmed after generics entered the market in November last year.
Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.
Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.